Literature DB >> 2165133

Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line.

C D Gregory1, M Rowe, A B Rickinson.   

Abstract

Epstein-Barr virus (EBV)-positive Burkitt's lymphoma (BL) biopsy cells and early passage BL cell lines have been reported as showing an unusual type of virus-cell interaction; at least two EBV latent proteins appear not to be expressed. Serial passage of such lines is often accompanied by a broadening of virus latent gene expression and a corresponding change in the cell surface/growth phenotype towards that shown by in vitro transformed lymphoblastoid cell lines (LCLs). The sequence of events, both viral and cellular, involved in this transition needs to be defined properly. In the present work, phenotypically distinct cell clones have been derived from early passage cultures of a BL cell line in phenotypic transition, thereby giving access to relatively stable cell populations through which the different EBV-B cell interactions within the parental line can be studied. Clones retaining the original BL biopsy cell phenotype (CD10/CD77-positive, activation antigen/adhesion molecule-negative) expressed the virus-encoded nuclear antigen EBNA 1 but not any of the other known latent proteins, EBNAs 2, 3a, 3b, 3c, -LP and latent membrane protein (LMP). Other clones which had developed an LCL-like phenotype (CD10/CD77-negative, activation antigen/adhesion molecule-positive) now expressed all the above latent proteins and also contained significant numbers of cells in lytic cycle. Phenotypic change occurring within the parental BL cell line itself was initiated in a small subpopulation of cells in which the virus-encoded proteins EBNA 2 and LMP were transiently induced to an unusually high level of expression; this was accompanied by the first detectable changes in cell surface phenotype, namely the increase of cellular adhesion molecules. Some control over EBNA 2/LMP expression then appeared to be re-imposed since the presumed clonal descendents of these cells stably expressed EBNA 2 and LMP at much reduced levels typical of those seen in conventional LCLs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165133     DOI: 10.1099/0022-1317-71-7-1481

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  133 in total

1.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Interferon regulatory factor 2 represses the Epstein-Barr virus BamHI Q latency promoter in type III latency.

Authors:  L Zhang; J S Pagano
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

3.  Epstein-barr virus (EBV) nuclear protein 2-induced disruption of EBV latency in the Burkitt's lymphoma cell line Akata: analysis by tetracycline-regulated expression.

Authors:  S Fujiwara; Y Nitadori; H Nakamura; T Nagaishi; Y Ono
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

Review 4.  Fortifying B cells with CD154: an engaging tale of many hues.

Authors:  J Gordon; J D Pound
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

5.  MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.

Authors:  Martin S Staege; Steven P Lee; Teresa Frisan; Josef Mautner; Siegfried Scholz; Alexander Pajic; Alan B Rickinson; Maria G Masucci; Axel Polack; Georg W Bornkamm
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

Review 6.  The expression and function of Epstein-Barr virus encoded latent genes.

Authors:  L S Young; C W Dawson; A G Eliopoulos
Journal:  Mol Pathol       Date:  2000-10

7.  Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis.

Authors:  I K Ruf; P W Rhyne; C Yang; J L Cleveland; J T Sample
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.

Authors:  Donna Hochberg; Jaap M Middeldorp; Michelle Catalina; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-19       Impact factor: 11.205

9.  Epstein-Barr virus utilizes Ikaros in regulating its latent-lytic switch in B cells.

Authors:  Tawin Iempridee; Jessica A Reusch; Andrew Riching; Eric C Johannsen; Sinisa Dovat; Shannon C Kenney; Janet E Mertz
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

10.  Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines.

Authors:  B C Schaefer; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.